Reactome | Resistance of ERBB2 KD mutants to lapatinib

Schema > Pathway > Entries

Resistance of ERBB2 KD mutants to lapatinib Show undefined attributes

authored	[InstanceEdit:9665241] Orlic-Milacic, Marija, 2019-10-30
created	[InstanceEdit:9665248] Orlic-Milacic, Marija, 2019-10-30
crossReference	[DatabaseIdentifier:12819431] BioModels Database:BIOMD0000000883 [DatabaseIdentifier:12020745] Mondo:0004992
dbId	9665251
disease	[Disease:1500689] cancer
displayName	Resistance of ERBB2 KD mutants to lapatinib
edited	[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
eventOf	[Pathway:R-HSA-9665230] Drug resistance in ERBB2 KD mutants - Homo sapiens
hasDiagram	true
hasEHLD	false
hasEvent	[FailedReaction:R-HSA-9665284] Resistant ERBB2 KD mutants do not bind lapatinib - Homo sapiens
isInDisease	true
isInferred	false
lastUpdatedDate	2023-06-07
literatureReference	[LiteratureReference:9649445] High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2 [LiteratureReference:9646435] Activating HER2 mutations in HER2 gene amplification negative breast cancer [LiteratureReference:9646493] Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study [LiteratureReference:9649397] Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib [LiteratureReference:9646787] Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) [LiteratureReference:9646776] EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation [LiteratureReference:9652195] Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 [LiteratureReference:9647026] An Acquired HER2^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
maxDepth	2
modified	[InstanceEdit:12819426] Weiser, Joel, 2026-02-23
name	Resistance of ERBB2 KD mutants to lapatinib
normalPathway	[Pathway:R-HSA-1227986] Signaling by ERBB2
releaseDate	2019-12-10
reviewStatus	[ReviewStatus:9821382] five stars
reviewed	[InstanceEdit:9662685] Kancha, Rama Krishna, 2019-09-16
schemaClass	Pathway
species	[Species:48887] Homo sapiens
stId	R-HSA-9665251
summation	[Summation:9665267] This pathway describes resistance of ERBB2 KD mutants to tyr...
updateTrackers	[UpdateTracker:9835729] Update Tracker - [Pathway:9665251] Resistance of ERBB2 KD mutants to lapatinib - v85:[updateContainedRLE]

Referrals

(updatedInstance)	[UpdateTracker:9835729] Update Tracker - [Pathway:9665251] Resistance of ERBB2 KD mutants to lapatinib - v85:[updateContainedRLE]
(hasEvent)	[Pathway:R-HSA-9665230] Drug resistance in ERBB2 KD mutants